|
|
Post by prosper on Aug 5, 2015 14:10:03 GMT -5
Fortune Mag featured an interview with the ceo of privately held Intarcia Therapeutics that appears to have completed trials of a drug delivery system that has multidrug delivery capabilities as Technosphere. They apparently have completed trials for a diabetic's implanted drug delivery device. Up to one year per treatment. Has anyone here gotten more knowledge than this? The Fortune feature was too small, like a 2 minute news bite, but it sounds as if it might affect us, although it sounds like it is more likely to affect the long lasting basal insulins. Any comments or updates would be greatly appreciated |
|
|
|
Post by mannmade on Aug 5, 2015 15:45:15 GMT -5
First I must disclose I have not seen it. Secondly am not too concerned until I would know more... I base this on the following, which I have to admit is really just a guess on my part as I do not have any real information.
1.) Sounds like it might be for Basal re:Diabetics
2.) Likely still a few years off from market
3.) Not sure how you dose various meds for up to one year
4.) Am curious how you use one implanted device to treat multiple issues in the same patient requiring different drugs and dosing, such as an insulin dependent diabetic who also gets migraines. Easier to have two separate inhales I would think.
5.) Lastly and most importantly... would you rather inhale or have a new implant every year. Especially for things like migraines that are not an every day occurence for most.
Now it may work well for oncology needs and other med needs, but if so, likely room for both. Just my opinion and 2 cents...
|
|
|
|
Post by prosper on Aug 5, 2015 15:51:38 GMT -5
Throw out those needles, here's a new way for diabetics to get treatment - Fortune
fortune.com/video/2015/07/23/throw-out-those-needles-heres-a-new-way-for-diabetics-to-get-insulin/
Here is the link to the interview. To address your question about dosing, I somehow come away with the impression that this is not insulin, but something that makes the body produce it. That is way outside my tech knowledge to know if that is what they meant. Please watch this and give me your opinion. The way the ceo talks it comes across as equally as innovative an approach as Technosphere/Afrezza |
|
|
|
Post by joeypotsandpans on Aug 5, 2015 16:42:05 GMT -5
|
|
|
|
Post by justsayin on Aug 6, 2015 13:36:35 GMT -5
Actually, the late-stage investigational drug referred to in the FORTUNE video interview is ITCA 650, and while my guess is that it's probably about 2 years away from commercialization, it already looks like it could create a new standard of care in type 2 diabetes, if and when approved. It is the result of the company's proprietary chemistry techniques that accomplish what is some amazing peptide stabilization so that exenatide can remain clinically viable for a year or more at body temperature. It's all done from a tiny titanium stick the size of a match that is place just under the surface of the skin in a patient's abdomen. Basically it is an osmotic mini-pump. From what I've read, it is designed to deliver continuous and consistent therapeutic level dosing without the typical nightmare of non-adherence found among so many patients with chronic disease like type 2 diabetes who need to take multiple oral medications or injections. ITCA 650 has already completed two Phase 3 trials, and another is supposed to be announced in the next few months. I believe it will be their head-to-head trial between ITCA 650 and market leader Januvia (from Merck). The full results of the first two Phase 3 studies were shared in early June 2015 at ADA in Boston, and they were quite impressive and seemed to be well received.
|
|
|
|
Post by mssciguy on Aug 6, 2015 13:47:59 GMT -5
it sounds like hype. Be very careful. Ten years to get Afrezza approved and you "guess" two years to commercialization. Guess again.
|
|
|
|
Post by justsayin on Aug 7, 2015 9:36:49 GMT -5
Yes, always "Be very careful." Two years to commercialization could be unrealistic in its time frame. Nobody can predict what the FDA review process will do. But that said, ITCA 650 is essentially a "de-risked" product because the drug itself (exenatide) has been on the market for a decade in tens of thousands in not hundreds of thousands or even millions of patients globally. So it is a very KNOWN entity in terms of safety and efficacy in a post-marketing and already commercialized sense, whereas truly novel compounds represent higher risk of unknown results in massive numbers of patients post launch. Also, I believe the tiny titanium stick device has been placed in tens thousands of patients for other situations. Hence, what I'd call a "de-risked" product compared to most. So as usual, all we can do is wait and see. But this shouldn't be quite as much of a 'wild card' as a first-in-class type of medication to come to market.
|
|
